Accordingly, modulation of the TLR4/NF-κB signaling pathway has been a therapeutic target for sepsis, and several candidates, such as eritoran and TAK-242, which are inhibitors of TLR4, have shown partial efficacy in both animal studies [9,10] and clinical trials [11,12]. The gene discussed is TLR4; the disease is Sepsis.